BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Brenipatide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Brenipatide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06606106-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Brenipatide: Phase 1 readout est. (NCT06606106)
DESCRIPTION:Brenipatide\, phase 1\, Obesity.\nStudy: A Study of LY3537031 i
 n Overweight\, Obese\, and Healthy Participants\nEstimated primary complet
 ion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 renipatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06606106
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165002-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Brenipatide: Phase 1 readout est. (NCT07165002)
DESCRIPTION:Brenipatide\, phase 1.\nStudy: A Study of the Pharmacokinetics 
 and Safety of LY3537031 in Participants With Normal Liver Function and Wit
 h Mild\, Moderate\, or Severe Liver Impairment\nEstimated primary completi
 on: November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/br
 enipatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07165002
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476118-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Brenipatide: Phase 1 readout est. (NCT07476118)
DESCRIPTION:Brenipatide\, phase 1\, Obesity.\nStudy: A Study of Brenipatide
  (LY3537031) in Healthy Participants With Overweight or Obesity\nEstimated
  primary completion: February 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07476118
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223840-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07223840)
DESCRIPTION:Brenipatide\, phase 2.\nStudy: A Study of Brenipatide in Adults
  Who Quit Smoking Cigarettes and Want to Avoid Relapse\nEstimated primary 
 completion: February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07223840
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545772-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07545772)
DESCRIPTION:Brenipatide\, phase 2.\nStudy: A Study of Brenipatide (LY353703
 1) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)\nEst
 imated primary completion: July 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07545772
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545759-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07545759)
DESCRIPTION:Brenipatide\, phase 2.\nStudy: A Study of Brenipatide (LY353703
 1) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)\nEstimat
 ed primary completion: September 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07545759
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410507-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07410507)
DESCRIPTION:Brenipatide\, phase 2\, Schizophrenia.\nStudy: A Study of Breni
 patide in Adult Participants With Schizophrenia\nEstimated primary complet
 ion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 renipatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07410507
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286175-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07286175)
DESCRIPTION:Brenipatide\, phase 2\, Bipolar Disorder.\nStudy: A Study of Br
 enipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07286175
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927309-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20271127
DTEND;VALUE=DATE:20271128
SUMMARY:Brenipatide: Phase na readout est. (NCT07927309)
DESCRIPTION:Brenipatide\, phase na.\nStudy: A Study of Brenipatide (LY35370
 31) Comparing Two Formulations in Healthy Adults\nEstimated primary comple
 tion: 27 November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07927309
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412756-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07412756)
DESCRIPTION:Brenipatide\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide in Adult Participants With Major Depressive Disorder\nE
 stimated primary completion: February 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07412756
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420283-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07420283)
DESCRIPTION:Brenipatide\, phase 2\, Opioid Use Disorder.\nStudy: A Study of
  Brenipatide in Participants With Opioid Use Disorder\nEstimated primary c
 ompletion: March 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07420283
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219173-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07219173)
DESCRIPTION:Brenipatide\, phase 2\, Asthma.\nStudy: A Study to Evaluate Bre
 nipatide Compared With Placebo in Adult Participants With Uncontrolled Mod
 erate to Severe Asthma\nEstimated primary completion: April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/brenipatide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07219173
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219966-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07219966)
DESCRIPTION:Brenipatide\, phase 3\, Alcohol Use Disorder.\nStudy: A Study o
 f Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
 \nEstimated primary completion: April 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07219966
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219953-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07219953)
DESCRIPTION:Brenipatide\, phase 3\, Alcohol Use Disorder.\nStudy: A Study o
 f Brenipatide in Participants With Alcohol Use Disorder\nEstimated primary
  completion: April 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07219953
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759245-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07759245)
DESCRIPTION:Brenipatide\, phase 2\, Chronic Obstructive Pulmonary Disease.\
 nStudy: A Study of Brenipatide (LY3537031) in Adult Participants With Mode
 rate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)\nEstimated pri
 mary completion: May 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/brenipatide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07759245
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928245-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07928245)
DESCRIPTION:Brenipatide\, phase 2\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide in Participants With Major Depressive Disorder\nEstimat
 ed primary completion: May 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/brenipatide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07928245
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775300-822@assetmemo.bio
DTSTAMP:20261121T004958Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brenipatide: Phase 3 readout est. (NCT07775300)
DESCRIPTION:Brenipatide\, phase 3\, Major Depressive Disorder.\nStudy: A St
 udy of Brenipatide (LY3537031) in Adult Participants With Major Depressive
  Disorder\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/brenipatide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07775300
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
